The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, i.e. strains resistant at least to isoniazid (INH) and rifampin (RMP), the two most powerful first-line drugs for the treatment of tuberculosis (TB), represents a worldwide health care problem. Patients with MDR strains should receive therapy based on individual drug susceptibility testing (DST) 1 including residual first-line (streptomycin, SM; ethambutol, EMB; and pyrazinamide, PZA) and second-line (ofloxacin, kanamycin, capreomycin, ethionamide, p-aminosalicylic acid, cycloserine) anti-TB drugs.
Pyrazinamide resistance in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Abkhazia / Pardini M.; Varaine F.; Hewison C.; Iona E.; Pataracchia M.; Orefici G.; Fattorini L.; Oggioni M.R.; Meacci F.; D'Amato V.; Andrew P.W.; Barer M.; Yesilkaya H.; Rinder H.; Rusch-Gerdes S.; Niemann S.; Orru G.; Varaine F.; Bonnet M.; Jarosz T.. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - STAMPA. - 19:1(2007), pp. 106-107. [10.1179/joc.2007.19.1.106]
Pyrazinamide resistance in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Abkhazia
Oggioni M. R.;
2007
Abstract
The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, i.e. strains resistant at least to isoniazid (INH) and rifampin (RMP), the two most powerful first-line drugs for the treatment of tuberculosis (TB), represents a worldwide health care problem. Patients with MDR strains should receive therapy based on individual drug susceptibility testing (DST) 1 including residual first-line (streptomycin, SM; ethambutol, EMB; and pyrazinamide, PZA) and second-line (ofloxacin, kanamycin, capreomycin, ethionamide, p-aminosalicylic acid, cycloserine) anti-TB drugs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
